Navigation Links
RI Hospital: Absence of specific enzyme in cartilage can lead to benign tumors in mice
Date:7/18/2013

PROVIDENCE, R.I. Rhode Island Hospital researchers have found that the absence of the Shp-2 enzyme near specialized cartilage cells can lead to the development of multiple benign cartilage tumors in mice, a model that recapitulates the rare human tumor syndrome metachondromatosis. Shp2 is an enzyme in the cell that regulates the activity of other proteins and signaling pathways. Mice lacking Shp2 formed two types of tumors: enchondromas and osteochondromas, and also developed deformed joints. The study is published online in advance of print in the journal Nature.

"Transgenic mouse models of human disease are powerful tools to gain a better understanding of disease processes and to test novel treatments," said lead author, Wentian Yang, Ph.D., of the department of orthopedics at Rhode Island Hospital. "In humans, some of these benign tumors will progress to malignant cartilage tumors, called chondrosarcomas, which are even more serious since they spread and can be fatal."

He continued, "Knowing the cell of origin for tumor formation can be helpful in developing new treatments since each type of cell has its weak points. Our research led to the discovery of a novel cartilage stem/progenitor cell population that is the cell of origin for the tumors in our model, and to the identification of a potential therapy for this rare disease. In the future, our model may also be useful for developing novel treatments for some forms of chondrosarcoma, a type of bone cancer."

Injury to the growth plate has been the assumed reason for the formation of osteochondromas, which look similar to a growth plate that has taken off in the wrong direction, causing bone and cartilage to grow out of the bone. This research demonstrates that one cause of osteochondromas is a molecular abnormality in an enzyme in a tiny group of cells near the growth plate, resulting in often large tumors growing out of the bone. These tumors are a very common in children.

"These findings put us one step closer to understanding how these tumors form," Yang said. "The next step will be to develop a way to stop the tumors from growing at an early stage so that they do not have to be surgically removed."


'/>"/>

Contact: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
Source:Eurekalert

Related biology news :

1. Rhode Island Hospital: Adult entertainment workers likely to benefit from health care intervention
2. RI Hospital: Use of PMP may increase demand for drug treatment, reduce painkiller abuse
3. Viable and fertile fruit flies in the absence of histone H3.3
4. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
5. Researchers create method to rapidly identify specific strains of illness
6. Epigenetic biomarkers may predict if a specific diet and exercise regimen will work
7. Turtle genome analysis sheds light on the development and evolution of turtle-specific body plan
8. Cutting specific pollutants would slow sea level rise
9. In autism, age at diagnosis depends on specific symptoms
10. Molecular basis identified for tissue specific immune regulation in the eye and kidney
11. Bisphenol A affects sex-specific reproductive behaviors in a monogamous animal species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology: